Author:
Kumar Nitin,Kalaiselvan Vivekanandan,Arora Mandeep Kumar
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Zahavi DJ, Weiner LM (2020) Monoclonal antibodies in cancer therapy Antibodies 9(3):34. https://doi.org/10.3390/antib9030034
2. Quinteros DA, Bermúdez JMA, Ravetti S, Cid AG, Allemandi DA, Palma SD (2017) Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery. In: Elsevier eBooks. 807–833. https://doi.org/10.1016/b978-0-323-46143-6.00025-7
3. Antibody therapeutics approved or in regulatory review in the EU or US - the antibody society. 2027 The Antibody Society. https://www.antibodysociety.org/resources/approved-antibodies/. Accessed 29 Oct 2023
4. Horta E, Bongiorno C, Ezzeddine M, Neil E (2020) Neurotoxicity of antibodies in cancer therapy: a review. Clin Neurol Neurosurg 188:105566. https://doi.org/10.1016/j.clineuro.2019.105566
5. Chen C, Wu B, Zhang C, Xu T (2021) Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int J Immunopharmacol 95:107498. https://doi.org/10.1016/j.intimp.2021.107498